Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT07213973Phase 2Recruiting
- Sponsor
- Incyte
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of povorcitinib in hidradenitis suppurativa (HS), sponsored by Incyte. Started Feb 2026; status: recruiting.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07213973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213973.